Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
Healthcare
$8.62 +0.12%
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
52W Low $6.36High $18.98
Volume 0.01M
Average 0.02M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$26.92M
FY 2025 · Annual
Net Income
-$25.31M
FY 2025 · Annual
Income Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 165.69K | 3.73M | 8.82M | 20K | 5.09K |
| Gross Profit | (165.69K) | (3.73M) | (8.82M) | (20K) | (5.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.88M | 2.59M | 8.82M | 19.6M | 18.75M |
| Selling, General & Admin | 2.8M | 5.49M | 6.64M | 8.19M | 7.44M |
| Operating Expenses | 4.7M | 4.69M | 15.46M | 27.79M | 26.92M |
| Depreciation & Amortization | 165.69K | 337K | 7K | 20K | 5.09K |
| EBITDA | (4.6M) | (8.09M) | (15.71M) | (28.08M) | (26.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.65M) | (8.43M) | (15.46M) | (27.81M) | (26.92M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 7.99K | 63K | 1.33M | 1.37M | 1.38M |
| Interest Expense | 985.33K | 0 | 177K | 0 | 0 |
| Other Income / Expenses | (8.86M) | (2.89M) | (426K) | (291K) | 1.79M |
| Income Before Tax | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.13M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (42.41K) | 5K | 0 | 0 | 175.01K |
| Net Income | (15.51M) | (11.32M) | (15.89M) | (28.1M) | (25.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| EPS (Diluted) | (7.73) | (3.81) | (2.21) | (2.94) | (1.73) |
| 2.01M | 2.97M | 7.2M | 9.56M | 14.6M | |
| 2.01M | 2.97M | 7.2M | 9.56M | 14.6M |
MSCL.TO Earnings Waterfall · TTM
TSX:MSCL.TO · Revenue to Net Income
Key Ratios
EPS$-1.80
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$27.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.80, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
No filings found.
How much revenue does MSCL.TO generate?
Satellos Bioscience Inc. (MSCL.TO) reported $0.00 of revenue in fiscal 2025.
Is MSCL.TO profitable?
Satellos Bioscience Inc. (MSCL.TO) reported -$25.31M of net income.
Continue the stock analysis
Jump to another research area for this company.